Sorrento's biotech buyouts bag CAR-T drugs

The headline here neatly summarizes almost all we know about this deal. Sorrento Therapeutics ($SRNE), closely allied with Patrick Soon-Shiong's fast-growing oncology drug empire, has bagged two private biotech companies, adding some CAR-T therapies to the mix. There's no word on which companies Sorrento bought, or what the exec team paid, but Sorrento says the deal fits neatly into its steadily growing pipeline for immuno-oncology therapies as well as new work on biosimilars. San Diego-based Sorrento says these new CAR-T therapies--which take T cells and equip them with chimeric antigen receptors to aim them straight at cancer cells--will make for promising combinations with its anti-PD1 checkpoint program and  anti-CTLA4 monoclonal antibodies. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.